A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

Phase 1, multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of QCZ484. In Part A, single ascending doses of QCZ484 are tested in healthy subjects, while in Part B, single doses of QCZ484 are tested in subjects with mild hypertension. One dose of QCZ484 is administered subcutaneously. This study was started by Argo Biopharma, and global sponsorship was transferred to Novartis.